


FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427C15	APPLICATION NO. 09/593,793
 SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Jiangchun Xu et al.			
		FILING DATE June 13, 2000	GROUP ART UNIT 1642 JUL 08 2004		

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	TECH CENTER 1600/2900 SUBCLASS IF APPROPRIATE
				TECH CENTER 1600/2900 SUBCLASS IF APPROPRIATE	
AA					
AB					
AC					
AD					
AE					
AF					
AG					

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>DB</i>	AP	Aspinall, J.O. et al., "Differential Expression of Apolipoprotein-D and Prostate Specific Antigen in Benign and Malignant Prostate Tissues," <i>Journal of Urology</i> 154: 622-628, August 1996.
<i>DB</i>	AQ	Fannon, M.R., "Gene expression in normal and disease states – identification of therapeutic targets," <i>Trends in Biotechnology</i> 14: 294-298, August 1996.
<i>DB</i>	AR	Garde, S.V. et al., "Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP)," <i>Cancer Letters</i> 78: 11-17, 1994.
<i>DB</i>		GenBank Database, Accession No. AA112574, May 29, 2003.
<i>DB</i>		Murphy, G. et al., "Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients," <i>Anticancer Research</i> 15: 1473-1480, 1995.

EXAMINER <i>Jiangchun Xu</i>	DATE CONSIDERED <i>8/23/04</i>
---------------------------------	-----------------------------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).